<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2019 [PPXK5GW761L0VHZ48WGR]. www.edgarsuite.com -->
<HEAD>
<TITLE>
 &nbsp;</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=center style='font:10pt Times New Roman;margin:0'><B>UNITED STATES</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Washington, D.C. 20549</B></P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>FORM 8-K</B></P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CURRENT REPORT</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Pursuant to Section 13 or 15(d) of</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>The Securities Exchange Act of 1934</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Date of Report (Date of earliest event reported):&#160;&#160; August 29, 2019</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>&#160;</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>MOUNT TAM BIOTECHNOLOGIES, INC.</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Exact name of registrant as specified in its charter)</P>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Nevada</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(State or other jurisdiction of incorporation)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<TABLE align=center style=border-collapse:collapse;width:60%><TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><B>333-192060</B></P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'><B>45-3797537</B></P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>(Commission File Number)</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>(I.R.S. Employer Identification No.)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:36pt;color:#000000'><FONT style='border-bottom:1px solid #000000'>106 Main Street #4E</FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Burlington, VT 05401</FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Address of principal executive offices)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(425) 214-4079</FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Registrant&#8217;s telephone number, including area code)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>N/A</P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Former name or former address, if changed since last report)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT face=Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT face=Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT face=Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'><FONT face=Wingdings>&#168;</FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&#160;</P>
<TABLE align=center style='border-collapse:collapse;border:0.5pt solid #000000'><TR><TD valign=top style='width:153.9pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>Title of each class</B></FONT></P>
</TD><TD valign=top style='width:135pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>Trading Symbol(s)</B></FONT></P>
</TD><TD valign=top style='width:189.9pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>Name of each exchange on which registered</B></FONT></P>
</TD></TR>
<TR><TD valign=top style='width:153.9pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>Common Stock, $0.0001 par value</FONT></P>
</TD><TD valign=top style='width:135pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>MNTM</FONT></P>
</TD><TD valign=top style='width:189.9pt;border:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt>OTCPINK</FONT></P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt;color:#212121;background-color:#FFFFFF'><FONT style=color:#000000>&#160;</FONT>Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt MS Gothic;margin:0;background-color:#FFFFFF'><FONT style='font-family:Times New Roman'>Emerging growth company &nbsp;&nbsp;&#9744;</FONT></P>
<P style='font:10pt inherit;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</P>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><FONT style=background-color:#FFFFFF><B>Item 1.01</B></FONT></KBD><KBD style=margin-left:72pt></KBD><FONT style=background-color:#FFFFFF><B>Entry into a Material Definitive Agreement.</B></FONT>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF><I>Amendments to Existing Loan Agreements and Notes</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><KBD style=margin-left:36pt></KBD><FONT style=background-color:#FFFFFF>On August 29, 2019, Mount Tam Biotechnologies, Inc., a Nevada corporation (the &#8220;Company&#8221;) entered into an amendment (the &#8220;First Note Amendment&#8221;) to that certain Line of Credit Agreement and related Promissory Note with Fromar Investments, LP, a Delaware limited partnership (&#8220;Fromar&#8221;), dated May 10, 2019 (collectively, the &#8220;Fromar Note&#8221;), whereby the maturity date of the Fromar Note was extended to October 31, 2019. All other provisions of the Fromar Note, as disclosed on the Company&#8217;s Current Report on Form 8-K filed with the Commission on May 16, 2019, remain in full force and effect. &#160;</FONT>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>Also on August 29, 2019, the Company entered into an amendment (the &#8220;Second Note Amendment&#8221;) to that certain Line of Credit Agreement and related Promissory Note with Climate Change Investigation, Innovation and Investment Company, LLC, a California limited liability company (&#8220;CC3I&#8221;), dated May 10, 2019 (collectively, the &#8220;CC3I Note&#8221;), whereby the maturity date of the CC3I Note was extended to October 31, 2019. All other provisions of the CC3I Note, as disclosed on the Company&#8217;s Current Report on Form 8-K filed with the Commission on May 16, 2019, remain in full force and effect.&#160;</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>The Company will use the time period afforded to it by virtue of the First Note Amendment and the Second Note Amendment to explore strategic options. &nbsp;Each of Fromar and CC3I has represented to the Company that if it is not fully satisfied with the Company&#8217;s progress made as of October 31, 2019, each intends to exercise its respective rights under the Fromar Note and the CC3I Note, respectively, including the foreclosure of the security interests granted to each of them in connection with the Fromar Note and the CC3I Note, respectively, as described on the Company&#8217;s Current Report on Form 8-K filed with the Commission on May 16, 2019.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>The foregoing descriptions of the First Note Amendment and the Second Note Amendment do not purport to be complete and are qualified in their entirety by the terms and conditions of the agreements themselves. Copies of the First Note Amendment and the Second Note Amendment are attached to this Current Report on Form&#160;8-K as Exhibits 10.1 and 10.2, respectively, and each is incorporated herein by reference.&#160;</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF><B>Item 9.01 Financial Statements and Exhibits.</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A name=co_internalToc_EXL_1 /><FONT style=background-color:#FFFFFF><B>&#160;</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>(d) Exhibits</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;margin-left:4.65pt><TR style=height:10.8pt><TD valign=middle style='width:63pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>Exhibit No.</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>&#160;</FONT></P>
</TD><TD valign=middle style='width:305pt;padding-top:1.8pt;padding-right:1.8pt;border-bottom:0.5pt solid #000000'><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>Description</FONT></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>10.1</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>&#160;</FONT></P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A href=mntm_ex10z1.htm style=text-decoration:none><FONT style='color:#0000FF;background-color:#FFFFFF;border-bottom:1px solid #0000FF'>First Note Amendment</FONT></A></P>
</TD></TR>
<TR style=height:10.8pt><TD valign=middle style=width:63pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><FONT style=background-color:#FFFFFF>10.2</FONT></P>
</TD><TD valign=middle style=width:29pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'>&nbsp;</P>
</TD><TD valign=middle style=width:305pt;padding-top:1.8pt;padding-right:1.8pt><P align=justify style='font:10pt Times New Roman;margin:0;color:#212121;background-color:#FFFFFF'><A href=mntm_ex10z2.htm style=text-decoration:none><FONT style='color:#0000FF;background-color:#FFFFFF;border-bottom:1px solid #0000FF'>Second Note Amendment</FONT></A></P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3.75pt;background-color:#919191;margin:15pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SIGNATURES</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:36pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>MOUNT TAM BIOTECHNOLOGIES, INC.</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD colspan=2 valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Date:&#160;&#160;&#160;</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>August 30, 2019</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>By: </P>
</TD><TD valign=top style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>/s/ <I>Richard Marshak</I></FONT></P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Name: </P>
</TD><TD valign=bottom style=white-space:nowrap><P style='font:10pt Times New Roman;margin:0'>Richard Marshak</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Title:</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Calibri;margin:0'>&nbsp;</P>
<P align=right style='font:10pt Times New Roman;margin:0'><A name=_iDocIDField_EOD /><FONT style=font-size:10pt>4814-2378-5122</FONT></P>
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "mntm_8k.htm", "description": "8-K", "secsgml_size_bytes": 18502}]
{"company-data": {"conformed-name": "Mount TAM Biotechnologies, Inc.", "cik": "0001589361", "assigned-sic": "2100", "irs-number": "453797537", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-192060", "film-number": "191070265"}, "business-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945", "phone": "(425) 214-4079"}, "mail-address": {"street1": "7250 REDWOOD BLVD, SUITE 300", "city": "NOVATO", "state": "CA", "zip": "94945"}, "former-company": [{"former-conformed-name": "TabacaleraYsidron, Inc.", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERAYSIDRON INC", "date-changed": "20140206"}, {"former-conformed-name": "TABACALERA YSIDRON INC", "date-changed": "20131016"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):   August 29, 2019
MOUNT TAM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of incorporation)
333-192060
45-3797537
(Commission File Number)
(I.R.S. Employer Identification No.)
106 Main Street #4E
Burlington, VT 05401
(Address of principal executive offices)
(425) 214-4079
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value
MNTM
OTCPINK
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 1.01
Entry into a Material Definitive Agreement.
Amendments to Existing Loan Agreements and Notes
On August 29, 2019, Mount Tam Biotechnologies, Inc., a Nevada corporation (the "Company") entered into an amendment (the "First Note Amendment") to that certain Line of Credit Agreement and related Promissory Note with Fromar Investments, LP, a Delaware limited partnership ("Fromar"), dated May 10, 2019 (collectively, the "Fromar Note"), whereby the maturity date of the Fromar Note was extended to October 31, 2019. All other provisions of the Fromar Note, as disclosed on the Company's Current Report on Form 8-K filed with the Commission on May 16, 2019, remain in full force and effect.
Also on August 29, 2019, the Company entered into an amendment (the "Second Note Amendment") to that certain Line of Credit Agreement and related Promissory Note with Climate Change Investigation, Innovation and Investment Company, LLC, a California limited liability company ("CC3I"), dated May 10, 2019 (collectively, the "CC3I Note"), whereby the maturity date of the CC3I Note was extended to October 31, 2019. All other provisions of the CC3I Note, as disclosed on the Company's Current Report on Form 8-K filed with the Commission on May 16, 2019, remain in full force and effect.
The Company will use the time period afforded to it by virtue of the First Note Amendment and the Second Note Amendment to explore strategic options.  Each of Fromar and CC3I has represented to the Company that if it is not fully satisfied with the Company's progress made as of October 31, 2019, each intends to exercise its respective rights under the Fromar Note and the CC3I Note, respectively, including the foreclosure of the security interests granted to each of them in connection with the Fromar Note and the CC3I Note, respectively, as described on the Company's Current Report on Form 8-K filed with the Commission on May 16, 2019.
The foregoing descriptions of the First Note Amendment and the Second Note Amendment do not purport to be complete and are qualified in their entirety by the terms and conditions of the agreements themselves. Copies of the First Note Amendment and the Second Note Amendment are attached to this Current Report on Form 8-K as Exhibits 10.1 and 10.2, respectively, and each is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
10.1
First Note Amendment
10.2
Second Note Amendment
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOUNT TAM BIOTECHNOLOGIES, INC.
Date:
August 30, 2019
By:
/s/
Richard Marshak
Name:
Richard Marshak
Title:
Chief Executive Officer
4814-2378-5122